High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, J. H. | - |
dc.contributor.author | Kweon, S. H. | - |
dc.contributor.author | Kim, H-J | - |
dc.contributor.author | Lee, T-H | - |
dc.contributor.author | Min, W-S | - |
dc.contributor.author | Kim, H-J | - |
dc.contributor.author | Kim, Y-K | - |
dc.contributor.author | Hwang, S. Y. | - |
dc.contributor.author | Kim, T. S. | - |
dc.date.accessioned | 2021-09-06T18:34:51Z | - |
dc.date.available | 2021-09-06T18:34:51Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012-06-26 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/108137 | - |
dc.description.abstract | BACKGROUND: Cytosine arabinoside-based chemotherapy coupled with anthracycline is currently the first-line treatment for acute myeloid leukaemia (AML), but diverse responses to the regimen constitute obstacles to successful treatment. Therefore, outcome prediction to chemotherapy at diagnosis is believed to be a critical consideration. METHODS: The mRNA expression of 12 genes closely involved in the actions of cytosine arabinoside and anthracycline was evaluated by real-time reverse transcriptase PCR (RT-PCR), in 54 diagnostic bone marrow specimens of M2-subtype AML. RESULTS: Low expression levels of ribonucleotide reductase M2 (RRM2) and high expression levels of topoisomerase 2 beta (TOP2B) were correlated with longer survival in a univariate analysis. Another interesting finding is that high ratios of TOP2B/RRM2 and TOP2B/TOP2 alpha (TOP2A) in a combined analysis were also shown to have a prognostic impact for longer survival with improved accuracy. Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P = 0.002) and overall survival (HR, 0.29; P = 0.005). CONCLUSION: Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype. British Journal of Cancer (2012) 107, 108-115. doi: 10.1038/bjc.2012.206 www.bjcancer.com Published online 24 May 2012 (C) 2012 Cancer Research UK | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject | TOPOISOMERASE-II-ALPHA | - |
dc.subject | DEOXYCYTIDINE KINASE | - |
dc.subject | DRUG-SENSITIVITY | - |
dc.subject | GENE-EXPRESSION | - |
dc.subject | BLAST CELLS | - |
dc.subject | CYTARABINE | - |
dc.subject | RESISTANCE | - |
dc.subject | IDENTIFICATION | - |
dc.subject | ANTHRACYCLINES | - |
dc.subject | DAUNORUBICIN | - |
dc.title | High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, J. H. | - |
dc.contributor.affiliatedAuthor | Kim, T. S. | - |
dc.identifier.doi | 10.1038/bjc.2012.206 | - |
dc.identifier.scopusid | 2-s2.0-84863001583 | - |
dc.identifier.wosid | 000305888400016 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF CANCER, v.107, no.1, pp.108 - 115 | - |
dc.relation.isPartOf | BRITISH JOURNAL OF CANCER | - |
dc.citation.title | BRITISH JOURNAL OF CANCER | - |
dc.citation.volume | 107 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 108 | - |
dc.citation.endPage | 115 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | TOPOISOMERASE-II-ALPHA | - |
dc.subject.keywordPlus | DEOXYCYTIDINE KINASE | - |
dc.subject.keywordPlus | DRUG-SENSITIVITY | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | BLAST CELLS | - |
dc.subject.keywordPlus | CYTARABINE | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | ANTHRACYCLINES | - |
dc.subject.keywordPlus | DAUNORUBICIN | - |
dc.subject.keywordAuthor | AML | - |
dc.subject.keywordAuthor | standard chemotherapy | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordAuthor | topoisomerase 2 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.